In Episode 4 of Beyond the Scale: The Ozempic Effect, hosts Terry Turner and Christian Simmons investigate the growing off-label use of GLP-1 drugs like Ozempic, Wegovy, and Mounjaro — especially among people without diabetes. 

As demand surges, so does the use of cheaper, unregulated compounded versions sold through telehealth and med spas. Metabolic health expert Dr. Matt Chalmers explains who should — and shouldn’t — be taking these powerful medications. Clinical pharmacist Dr. Elizabeth Van Dril breaks down what off-label prescribing really means and when it can be dangerous. 

Rob Andrews, former Congressman and now CEO of the Health Transformation Alliance, raises alarms about the FDA’s limited oversight of compounding pharmacies. With stricter federal rules now in place, are patients any safer? And what risks still remain? This episode explores how access can outpace oversight — and why that’s a dangerous mix with drugs as potent as GLP-1s.

Learn more at Drugwatch.com.